

## Building a Resilient Health Union: Security, Access and Competitiveness

### TUESDAY 24 JUNE 2025

17.30 – 19.30



Welcome cocktail and registration – Ballroom foyer

### WEDNESDAY 25 JUNE 2025

14.00 – 15.00



Welcome coffee and registration

15.00 – 15.15



Opening address: Katarzyna Kacperczyk, Deputy Minister of Health, Poland (inv)

15.15 – 16.15



Session 1 - Levelling up the European Health Union

This opening keynote will feature a high-level political debate on the European Commission's key priorities for advancing the European Health Union. The session will delve into some of the pivotal initiatives that will shape the new legislative mandate 2024-2029. These include the anticipated adoption of the revision of the pharmaceutical legislation as well as two major health industrial policy Acts - Critical Medicines and Biotech – which are expected to boost the competitiveness of the industry and address the security of medicines supply. Speakers will discuss the way forward to improve equitable and timely access to medicines, strengthening health security while ensuring the competitiveness and sustainability of the off-patent medicines sector.

#### Moderator:

#### Panellists

- **Stephan Eder**, President, Medicines for Europe
- **Olivér Várhelyi**, Commissioner, Health and Food Safety, European Commission (inv)
- **Frank Vandenbroucke**, Deputy Prime Minister and Minister of Social Affairs and Public Health, Belgium (inv)

16.15 – 16.45



Networking coffee break



16.45 – 18.20



**Session 2 – Forging a competitive future for European manufacturing through sound industrial policies**

This session will discuss into the Critical Medicines Act and the Biotech Act, two transformative legislative proposals aimed at ensuring Europe's open strategic autonomy in the area of biopharmaceutical manufacturing. The panel will address structural vulnerabilities in the pharmaceutical supply chain, which became evident during recent global crises, and discuss what has been done to date to resolve them and how the new European Commission's proposals can contribute to nurturing and expanding a future-proof off-patent industrial ecosystem in Europe.

**Moderator:** Katerina Patavou, Head of European Public Affairs, PEF, Greece

**Panellists**

- **Representative of the European Commission (TBC)**
- **Thomas Courbe**, Director General, French Ministry of Industry of Directorate-General for Enterprise
- **Elisabeth Stampa**, Chair at Medichem SA and Vice president at Medicines for Europe
- **Alexandra Moulson**, Head of Product Development, Polpharma Biologics (Biologicals)

18.20 – 18.30



**Closing address: Adrian van den Hoven, Director General, Medicines for Europe**

19.30



**Conference dinner**

**THURSDAY 26 JUNE 2025**

08.30 – 09.00



**Start of the day coffee**

09.00 – 09.30



**Spotlight session – Bridging skill gaps in biotech**

Biotech manufacturing has gone through a transformative evolution in the past 10 years. The next decade will also see loss of exclusivities across biological medicines involving new technological platforms e.g. gene therapies, cell therapies, mRNA. New technologies, environmental focus (eg energy & water consumption) and digitalisation require a highly skilled workforce for which there is increasing competition. This spotlight session will explore how companies and governments can partner to bridge these skill gaps and build strategies for the future.



**Moderator: Julie-Marechal Jamil**, Sr Director Pharmaceutical Policy & Head of Human Resources, Medicines for Europe

**Speakers**

- **Erik Bogesch**, Head of Biotechnology Business Unit, Gedeon Richter
- **Jean-Marc Bourez**, CEO, European Institute of Innovation and Technology (EIT) Health

09.30 – 10.45



**Session 3 –Delivering access to medicines in the context of the European Green Deal**

The mission of the off-patent industry is to ensure a broad portfolio of medicines that are available, affordable, and accessible to patients across Europe. We are committed to minimizing our impact on the environment while maintaining a reliable supply of medicines. The European Green Deal introduces significant regulatory challenges that directly and indirectly impact the pharmaceutical industry, including generic manufacturers. The Urban Wastewater Treatment Directive stands out in particular as an unprecedented challenge for the sector. While these changes present undeniable issues and demand closer coordination between healthcare and environment policymaking, some of them also open up opportunities for innovation and progress. This session will provide an honest look at the challenges and opportunities these changes bring. Join us to explore how we can align environmental ambitions with the critical goal of ensuring universal access to medicines, paving the way for a more sustainable and competitive future.

**Moderator: Adrian van den Hoven**, Director General, Medicines for Europe

**Speakers**

- **Bastiaan Venhuis**, Senior Policy Advisor at the Department of Pharmaceuticals and Medical Technology, The Netherlands
- **Mona Arnold**, Principal Scientist, VTT Technical Research Centre of Finland
- **Richard Bergström**, Vice President European Affairs, IQVIA
- **Steffen Saltofte**, CEO, Zentiva

10.45 – 11.15



**Networking coffee break**

11.15 – 12.45



**Session 4 – A new deal for security of supply**

This session will focus on creating a new framework for equitable access to medicines by addressing key issues in procurement, pricing, and market dynamics. We will explore the current state of play and the adjustments needed in these areas to ensure continued sustainability of health budgets as well as long-term security in the supply of medicines. Speakers will provide insights and share national best practices, laying the foundation for a new deal for generic medicines.

**Moderator: Arnaud Maheas**, Head of Public Affairs, Sandoz

**Speakers**

- **Laure Geslin**, Team Leader, European Commission's Directorate-General for Health and Food Safety (DG SANTE) (inv)
- **Michal Nitka**, Senior Vice President, Generics Head Europe & OTC Global Head, Teva
- **Artur Cwiok**, Head of Europe and Canada, Viatrix
- **Paul Tredwell**, Executive Vice President, Accord Healthcare
- **Walter Van Dyck**, Full Professor and Partner, Vlerick Business School

12.45 – 13.45



**Networking buffet lunch**

13.45 – 15.15



**Session 5 – Innovating together: collaborative solutions for today's health challenges**

Join us for a dynamic session where key actors from across the healthcare ecosystem will share the most pressing challenges they are facing in their day-to-day work. From equity of access to shortages and sustainability of health budgets, in this interactive session industry leaders and health stakeholders will try to find innovative solutions to these issues and shape the health ecosystem of tomorrow.

**Moderator: David Jauch**, Vice President Governmental Affairs & Public Policy, Fresenius Group

**Speakers**

- **Benedetta Baldini**, Senior Health Policy Advisor, ESIP
- **Anca Toma**, Executive Director, EPF (inv)
- **Roisin O'Hare**, Lead Clinical Education Pharmacist, Craigavon Area Hospital, Southern Health and Social Care Trust, Northern Ireland (inv)
- **Lucas Sigman**, Chair, IGBA's CEO Advisory Committee, Member of the M4E's Executive Committee and Chief Executive Officer, Insud Pharma S.L.
- **Theodore E. Tryfon**, Vice President and co CEO, ELPEN Group
- **Markus Sieger**, CEO, Polpharma Group

15.15 – 15.30



**Closure of the conference: Adrian van den Hoven**, Director General, Medicines for Europe

## Gold Sponsors



**31<sup>ST</sup>**  
**ANNUAL**  
**CONFERENCE**  
THE HOTEL, BRUSSELS

**25 - 26**  
**JUNE**  
2025

 **medicines**  
for europe  
better access. better health.

---

## Silver Sponsors

---

**Baxter**

  
INSUD PHARMA

**teva**

## Media Partner

**GaBi**

For further information and to register for the Annual Medicines for Europe Conference, click [here](#).